JP2013540114A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540114A5
JP2013540114A5 JP2013530690A JP2013530690A JP2013540114A5 JP 2013540114 A5 JP2013540114 A5 JP 2013540114A5 JP 2013530690 A JP2013530690 A JP 2013530690A JP 2013530690 A JP2013530690 A JP 2013530690A JP 2013540114 A5 JP2013540114 A5 JP 2013540114A5
Authority
JP
Japan
Prior art keywords
solvate
salt
formula
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530690A
Other languages
English (en)
Japanese (ja)
Other versions
JP5933562B2 (ja
JP2013540114A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/066658 external-priority patent/WO2012041805A1/de
Publication of JP2013540114A publication Critical patent/JP2013540114A/ja
Publication of JP2013540114A5 publication Critical patent/JP2013540114A5/ja
Application granted granted Critical
Publication of JP5933562B2 publication Critical patent/JP5933562B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530690A 2010-09-29 2011-09-26 N−カルボキシアルキル−アウリスタチンおよびその使用 Expired - Fee Related JP5933562B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10181966 2010-09-29
EP10181966.2 2010-09-29
EP11158466 2011-03-16
EP11158466.0 2011-03-16
PCT/EP2011/066658 WO2012041805A1 (de) 2010-09-29 2011-09-26 N-carboxyalkyl-auristatine und ihre verwendung

Publications (3)

Publication Number Publication Date
JP2013540114A JP2013540114A (ja) 2013-10-31
JP2013540114A5 true JP2013540114A5 (cg-RX-API-DMAC10.html) 2014-09-18
JP5933562B2 JP5933562B2 (ja) 2016-06-15

Family

ID=44674811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530690A Expired - Fee Related JP5933562B2 (ja) 2010-09-29 2011-09-26 N−カルボキシアルキル−アウリスタチンおよびその使用

Country Status (7)

Country Link
US (2) US8987209B2 (cg-RX-API-DMAC10.html)
EP (1) EP2621508B1 (cg-RX-API-DMAC10.html)
JP (1) JP5933562B2 (cg-RX-API-DMAC10.html)
CN (1) CN103379912B (cg-RX-API-DMAC10.html)
CA (1) CA2813056C (cg-RX-API-DMAC10.html)
ES (1) ES2553874T3 (cg-RX-API-DMAC10.html)
WO (1) WO2012041805A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5933562B2 (ja) 2010-09-29 2016-06-15 シアトル ジェネティックス, インコーポレイテッド N−カルボキシアルキル−アウリスタチンおよびその使用
US9029406B2 (en) 2011-03-16 2015-05-12 Seattle Genetics, Inc N-carboxyalkylauristatins and use thereof
JP6088488B2 (ja) * 2011-04-21 2017-03-01 シアトル ジェネティックス, インコーポレイテッド 新規な結合剤−薬物複合体(adc)およびそれらの使用
EP2850059A4 (en) 2012-05-15 2016-06-29 Concortis Biosystems Corp CONJUGATES OF MEDICATION, METHODS OF CONJUGATION AND USE THEREOF
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US10836821B2 (en) 2013-10-15 2020-11-17 Sorrento Therapeutics, Inc. Drug-conjugates with a targeting molecule and two different drugs
EP3753578A1 (en) 2013-12-17 2020-12-23 Novartis AG Cytotoxic peptides and conjugates thereof
LT3134124T (lt) 2014-04-25 2019-05-27 Pierre Fabre Médicament Igf-1r antikūno ir vaisto konjugatas, ir jo panaudojimas vėžio gydymui
PT3134125T (pt) 2014-04-25 2020-01-13 Pf Medicament Conjugado-fármaco-anticorpo e sua utilização para o tratamento de cancro
MX2016016515A (es) 2014-06-13 2017-04-27 Novartis Ag Derivados de auristatina y conjugados de los mismos.
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
CA2975383C (en) 2015-01-28 2023-09-12 Sorrento Therapeutics, Inc. Antibody drug conjugates comprising dolastatin derivatives
CN106279352B (zh) 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 海兔毒素10的衍生物及其应用
CN118562004A (zh) 2016-12-16 2024-08-30 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
KR20200099123A (ko) * 2017-12-15 2020-08-21 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 생체활성 접합체, 이의 제조 방법 및 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
CA2315230C (en) 1998-01-09 2004-06-29 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Anti-cryptococcal peptides
WO2000069472A2 (en) 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
SI2357006T1 (sl) 2002-07-31 2016-01-29 Seattle Genetics, Inc. Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
EP3505191A1 (en) 2004-11-12 2019-07-03 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP3498289A1 (en) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
DK2845866T3 (en) 2006-10-27 2017-07-10 Genentech Inc Antibodies and immunoconjugates and their applications
UA94628C2 (ru) * 2006-10-27 2011-05-25 Дженентек, Инк. Гуманизированное моноклональное антитело, которое связывается с steap-1, и его применение
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック, インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
PL2265283T3 (pl) 2008-03-18 2015-03-31 Seattle Genetics Inc Koniugaty aurystatyny lek łącznik
CA2801971C (en) 2010-06-10 2018-07-24 Hans-Georg Lerchen Novel auristatin derivatives and their use
JP5933562B2 (ja) 2010-09-29 2016-06-15 シアトル ジェネティックス, インコーポレイテッド N−カルボキシアルキル−アウリスタチンおよびその使用
US9029406B2 (en) 2011-03-16 2015-05-12 Seattle Genetics, Inc N-carboxyalkylauristatins and use thereof
JP6088488B2 (ja) 2011-04-21 2017-03-01 シアトル ジェネティックス, インコーポレイテッド 新規な結合剤−薬物複合体(adc)およびそれらの使用
CA2859255A1 (en) 2011-12-14 2013-06-20 Seattle Genetics, Inc. New antibody drug conjugates (adcs) and the use thereof

Similar Documents

Publication Publication Date Title
JP2013540114A5 (cg-RX-API-DMAC10.html)
JP2013533228A5 (cg-RX-API-DMAC10.html)
TW201740979A (zh) 熱休克蛋白(hsp)90抑制劑藥物共軛物
JP2015532295A5 (cg-RX-API-DMAC10.html)
CY1106784T1 (el) Υποκατεστημενα παραγωγα φαινυλ προπιονικου οξεος ως συναγωνιστες του ανθρωπινου υπεροξυσωματικου πολλαπλασιαστη - ενεργοποιημενου υποδοχεα αλφα (ppar)
JP2013231086A (ja) 化学療法の強化方法
CN1396830A (zh) 含有双膦酸盐的肠胃外药物组合物
JP2013537195A5 (ja) 疾患を治療するための医薬品及び同医薬品を含むキット
JP2020507589A5 (cg-RX-API-DMAC10.html)
JP2005506352A5 (cg-RX-API-DMAC10.html)
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
JP2007505877A5 (cg-RX-API-DMAC10.html)
JP2010511701A5 (cg-RX-API-DMAC10.html)
JP2016507571A (ja) フッ化インテグリンアンタゴニスト
JP2005508337A5 (cg-RX-API-DMAC10.html)
JP2010527985A5 (cg-RX-API-DMAC10.html)
JP2010505865A5 (cg-RX-API-DMAC10.html)
JP2018529648A5 (cg-RX-API-DMAC10.html)
US11883423B2 (en) Nucleobase analogue derivatives and their applications
JP2013536819A (ja) 緑内障および高眼圧症の処置のためのアデノシンa1アゴニスト
CN105246483A (zh) 用于γ-谷氨酰循环调节的方法和组合物
AU2008236994A1 (en) Method of treating melanoma
WO2009023876A1 (en) Method of treating non-small cell lung cancer
JP2018512390A (ja) Psmaリガンド−チューブリシン化合物を用いた癌の処置方法
JP2010535203A5 (cg-RX-API-DMAC10.html)